Media stories about AstraZeneca (NYSE:AZN) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. AstraZeneca earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.0785514378963 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
- Zacks: Analysts Anticipate AstraZeneca plc (AZN) to Post $0.46 Earnings Per Share (americanbankingnews.com)
- AstraZeneca’s oncology drugs receive regulatory boost (biospectrumasia.com)
- AstraZeneca launches mentoring collaboration with Lucy Cavendish College (cambridgeindependent.co.uk)
- Could Petrofac Limited, Diageo plc, AstraZeneca plc and Micro Focus International plc surge higher? (investomania.co.uk)
- AstraZeneca PLC, (NYSE: AZN) – Beta Factor Evaluation (stocksnewstimes.com)
Several equities analysts have recently issued reports on AZN shares. Zacks Investment Research upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, March 20th. JPMorgan Chase upgraded AstraZeneca from a “neutral” rating to an “overweight” rating in a report on Friday, December 29th. BMO Capital Markets set a $38.00 target price on AstraZeneca and gave the stock a “buy” rating in a report on Wednesday, January 10th. Jefferies Group upgraded AstraZeneca from a “hold” rating to a “buy” rating and lifted their target price for the stock from $28.43 to $36.70 in a report on Monday, March 19th. Finally, Leerink Swann restated a “market perform” rating and issued a $36.00 target price (up from $33.00) on shares of AstraZeneca in a report on Thursday, January 18th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $38.12.
AstraZeneca (NYSE:AZN) last announced its quarterly earnings results on Friday, February 2nd. The company reported $1.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.86. AstraZeneca had a return on equity of 34.74% and a net margin of 13.36%. The company had revenue of $5.78 billion during the quarter, compared to analysts’ expectations of $5.49 billion. During the same quarter in the previous year, the firm earned $1.21 earnings per share. The business’s quarterly revenue was up 3.4% compared to the same quarter last year. sell-side analysts forecast that AstraZeneca will post 1.7 earnings per share for the current fiscal year.
The business also recently declared a semiannual dividend, which was paid on Monday, March 19th. Shareholders of record on Friday, February 16th were given a $0.95 dividend. The ex-dividend date of this dividend was Thursday, February 15th. This represents a dividend yield of 5.62%. AstraZeneca’s dividend payout ratio is currently 32.01%.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.